Home / Company / Invectys’ achievements

Invectys’ achievements

Main achievements

  • Raised over 38 Millions €
  • Moved 2 products into phase II clinical trials
  • 15 patents filed
  • Ongoing 2 phase II clinical trials in the USA and in France

INVAC-1 DNA Vaccine  Phase I/II Clinical Trial Summary

Design

  • 3 cohorts with 100, 400 and 800 µg doses of INVAC-1  (n=3 per cohort)
  • Extension cohort 800 µg (n=11)
  • Treatment delivered monthly by intradermal injection. 3 cycles per protocol

Objectives

  • Toxicity, tolerance, safety and immune responses
  • Efficiency and immune response duration

Safety

  • Vaccine treatment well tolerated
  • No Dose Limiting Toxicity observed
  • No Serious Adverse Events

Efficacy

  • 60% of patients demonstrated stabilized disease
  • 14 of 20 patients survived for 12-28 months after treatment
  • 50% of patients showed anti-telomerase immune responses in blood